论文发表 (#Co-first author, *Corresponding author)
1、Fan Xing, Xuemei Wang, Zeying Li, Liangying Zheng, Zuda Huang, Jieqing Guo, Zhihui Xi, Huolun Feng, Baijin Xia, Yingtong Lin, Fei Yu, Jie Chen*, and Hui Zhang*.Specific loading of oncolytic VSV on CAR enhances CAR-T cell signaling and antitumor activity. J Exp Med. 2025 Nov 3;222(11):e20241851.（IF=13.5，医学1区）
2、Xin Guo#, Huolun Feng#, Zhihui Xi#, Ji Zhou, Zuda Huang, Jieqing Guo, Jiabin Zheng, Zejian Lyu, Yongfeng Liu, Jianlong Zhou, Yucheng Zhang, Yuhan Zhang, Mingxi Chen, Yong Li* and Fan Xing*. Targeting TBK1 potentiates oncolytic virotherapy via amplifying ICAM1-mediated NK cell immunity in chemo-resistant colorectal cancer. Journal for Immunotherapy of Cancer. 2025 Jun 8;13(6):e011455. (IF=10.6, 医学1区)
3、Dandan Zhu#, Zeying Li#, Huolun Feng#, Jiabin Zheng#, Xiao Xiao, Zuda Huang, Liangying Zheng, Jieqing Guo, Fa Ling, Yong Li* and Fan Xing*. EZH2 inhibition and 5-Azacytidine enhance anti-tumor immunity in PTEN-deficient glioblastoma by activation viral mimicry response. Journal for Immunotherapy of Cancer. 2025 Jun 13;13(6):e011650. (IF=10.6, 医学1区)
4、Xueqin Chen#, Jun Liu#, Yuequan Zeng#, Fang Wang, Zexiong Cheng, Yuqin Li, Guopeng Pan, Shangqi Yang, Yuling Chen, Qing Li, Xi Shen, Ying Li, Zixi Qin, Jiahong Chen, Youwei Huang, Xiangyu Wang, Yuli Lu, Minfeng Shu, Yubo Zhang, Guocai Wang, Kai Li, Xi Lin*, Fan Xing* and Haipeng Zhang*. IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma. Nature Communications. 2023 (IF=17.0, 综合一区TOP)
5、Zixi Qin#, Youwei Huang#, Zeying Li#, Guopeng Pan, Liangying Zheng, Xiao Xiao, Fang Wang, Jiahong Chen, Xueqin Chen, Xi Lin, Kai Li, Guangmei Yan, Haipeng Zhang*, Fan Xing*. Glioblastoma vascular plasticity limits effector T-cell infiltration and is blocked by cAMP activation. Cancer Immunology Research. 2023;CIR-22-0872. (IF=10.02, 医学一区TOP)
6、Jiabin Zheng#, Huolun Feng#, Jiatong Lin#, Jianlong Zhou, Zhihui Xi, Yucheng Zhang, Fa Ling, Yongfeng Liu, Junjiang Wang, Tieying Hou*, Fan Xing*, Yong Li*. KDM3A Ablation Activates Endogenous Retrovirus Expression to Stimulate Antitumor Immunity in Gastric Cancer. Advanced Science. 2024 Jul 19:e2309983. (IF=14.3, 综合一区)
7、Youwei Huang#, Fang Wang#, Xi Lin#, Qing Li, Yuli Lu, Jiayu Zhang, Xi Shena, Jingyi Tan, Zixi Qin, Jiahong Chen, Xueqin Chen, Guopeng Pan, Xiangyu Wang, Yuequan Zeng, Shangqi Yang, Jun Liu, Fan Xing*, Kai Li,* and Haipeng Zhang*. Nuclear VCP drives colorectal cancer progression by promoting fatty acid oxidation. PNAS. 2023;120(41):e2221653120. (IF= 11.1, 医学一区TOP)
8、Jingshu Xiao#, Jiangming Liang#, Junjie Fan，Panpan Hou, Xiaodong Li，Haipeng Zhang，Kai Li，Lang Bu, Miao He, Ping Li, Yongheng Zhong, Liping Guo, Penghui Jia, Qiaoqiao Xiao, Junyu Wu, Hong Peng1, Chunmei Li, Fan Xing* and Deyin Guo*. CDK4/6 inhibition enhances oncolytic therapy by potentiating tumor-selective cell killing and T cell activation in glioblastoma. Cancer Research, 2022 Sep 16;82(18):3359-3374.（IF= 13.312，医学一区TOP)
9、Fan Xing#, Jingshu Xiao#, Junyu Wu#, Jiaming Liang, Xiaoyu Lu, Liping Guo, Ping Li, Panpan Hou, Chunmei Li, Deyin Guo*. Modulating the tumor microenvironment via oncolytic virus and PI3K inhibition synergistically restores immune checkpoint therapy response in PTEN-deficient glioblastoma, Signal Transduction and Targeted Therapy, 2021 Jul 28;6(1):275. (IF= 38.1, 医学一区TOP)
10、Fan Xing#, Yizhao Luan#, Jing Cai#, .... Zhi Xie*, Wenbo Zhu*, Guangmei Yan*. The Anti-Warburg Effect Elicited by the cAMP-PGC1 alpha Pathway Drives Differentiation of Glioblastoma Cells into Astrocytes, Cell Reports, 2017 Jan 10;18(2):468-481. （IF= 9.995，生物学一区TOP）
11、Junyu Wu#, Chunyan Wu#, Fan Xing#, Liu Cao#, Weijie Zeng, Liping Guo, Ping Li1, Yongheng Zhong, Hualian Jiang, Manhui Luo, Guang Shi, Lang Bu, Yanxi Ji, Panpan Hou, Hong Peng, Junjiu Huang, Chunmei Li, Deyin Guo*. Endogenous reverse transcriptase and RNase H-mediated antiviral mechanism in embryonic stem cells. Cell Research. 2021 Sep;31(9):998-1010. (，IF= 46.3，生物学一区TOP)
12、Kai Li#, Cheng Hu#, Fan Xing#,...Guangmei Yan, Haipeng Zhang*, Yuan Lin*. Deficiency of the IRE1 alpha-Autophagy Axis Enhances the Antitumor Effects of the Oncolytic Virus M1, Journal of Virology, 2018 Feb 26;92(6): e01331-17. (IF= 5.4，医学二区)
13、Haipeng Zhang#, Kai Li#, Yuan Lin#, Fan Xing, Xiao Xiao, Jing Cai, Wenbo Zhu, Jiankai Liang, Yaqian Tan, Liwu Fu, Fang Wang, Wei Yin, Bingzheng Lu, Pengxin Qiu, Xingwen Su, Shoufang Gong, Xuetao Bai, Jun Hu*, Guangmei Yan*. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma, Science Translational Medicine, 2017 Aug 23; 9(404):eaam7996. (IF= 19.319, 医学一区)
主持基金项目：
1．国家自然科学基金面上项目，82173829，靶向抑制周期蛋白依赖性激酶4/6促进溶瘤病毒抗恶性胶质瘤的效应及其机制研究，2022/01- 2025/12，55万，在研，主持。
2. 国家自然科学基金青年项目，81803568，cAMP信号激动剂对恶性胶质瘤血管新生和血管正常化的影响及机制研究，2019/01-2021/12，21万元，结题，主持。
3．广东省“特支计划”青年拔尖人才，2023TQ07Y333，装载溶瘤病毒的CAR/TCR-T的新型肿瘤生物治疗策略开发，2024/09-2026/09，50万，在研，主持。
4. 南方医科大学“南医科技攀峰青年人才培养专项计划”，G623281132，溶瘤病毒疗法，2023/12-2025/12，20万，在研，主持。
5. 广东省人民医院引进人才配套经费（杰出青年医学人才），KY0120220257，溶瘤病毒疗法及其增效策略研究，2022/06-2027/06，200万，在研，主持。
6. 广东省人民医院“双青人才计划”-优秀青年人才项目，KY012023333，溶瘤病毒与肿瘤免疫治疗，2023/06-2028/05，250万，在研，主持。
7. 广东省自然科学基金面上项目，2018A030310099，cAMP信号激动诱导恶性胶质瘤细胞血管正常化及机制研究，2018/06-2021/06，10万元，结题，主持。
8. 广州市科技计划青年博士启航项目，SL2023A04J02326，重组溶瘤病毒rVSV-GSDME抗恶性胶质瘤的增效作用和机制研究，2024/01-2025/12，5万，在研，主持。
9.深圳市优秀科技创新人才培养项目，工程化溶瘤病毒克服PTEN缺陷胶质瘤免疫治疗抵抗的效应和机制, RCBS20200714114923232，2021/03-2023/03，20万元，结题，主持。
10. 深圳市科技计划自由探索项目，JCYJ20170818162249554，诱导分化剂对恶性胶质瘤血管生长和成熟的影响及其机制研究，2018/03-2021/03， 25万元，结题，主持。
研究生申请材料：
将个人简历（含个人基本信息、学习经历、工作经历、科研业绩、联系方式、论文发表目录及引用情况等）、已发表论文全文PDF、以及其他能证明本人科研水平的相关资料（可选）发送至xingfan@gdph.org.cn